Supplements for Secondary Hypogonadism: What the Evidence Actually Shows

What Is Secondary Hypogonadism and Why Do Supplements Get Attention?

Secondary hypogonadism occurs when the hypothalamic-pituitary-gonadal (HPG) axis fails to send adequate gonadotropin signals to the testes. Testosterone drops, but LH and FSH remain low or inappropriately normal rather than rising in compensation [1]. Obesity, opioid use, sleep apnea, and chronic stress are the most common acquired causes.

Because the defect sits upstream of the testes, the axis can sometimes be reactivated. That biological reality fuels interest in supplements and lifestyle changes that might "restart" gonadotropin secretion without exogenous testosterone. The Endocrine Society's 2018 clinical practice guideline states: "Clinicians should consider addressing reversible factors that contribute to low testosterone, including obesity and medications, before initiating testosterone therapy" [1]. This recommendation gives evidence-based lifestyle modification a clear clinical mandate. Still, most supplements marketed as testosterone boosters rely on animal models, tiny sample sizes, or no controlled data at all. The sections below sort signal from noise by focusing on randomized, placebo-controlled human trials published on PubMed-indexed journals.

Vitamin D: Effective Only When You Are Deficient

Correcting a true vitamin D deficit raises testosterone. That claim has strong support from a single well-designed RCT, but extending it to men with adequate vitamin D levels is not justified.

Pilz et al. randomized 54 overweight men with vitamin D levels below 20 ng/mL to receive 3 to 332 IU of vitamin D daily or placebo for 12 months. The supplementation group saw total testosterone rise from 10.7 nmol/L to 13.4 nmol/L, while the placebo group showed no significant change [2]. That 2.7 nmol/L (~78 ng/dL) increase is clinically meaningful for a man hovering near the lower reference range. A cross-sectional analysis from the European Male Ageing Study (N=3,369) confirmed an independent association between 25(OH)D levels and total testosterone after adjusting for BMI and comorbidities [3].

The catch: men with 25(OH)D already above 30 ng/mL do not see further testosterone gains from supplementation. Testing your vitamin D level before supplementing is worth the $30 lab draw. For deficient men, 2,000-4 to 000 IU daily of vitamin D3 with a fat-containing meal is a reasonable repletion strategy while monitoring serum levels at 8-12 weeks.

Zinc: A Micronutrient the HPG Axis Depends On

Zinc participates directly in Leydig cell steroidogenesis and pituitary gonadotropin release. Marginal zinc deficiency is common in older adults, athletes with high sweat losses, and men on proton pump inhibitors.

Prasad et al. demonstrated that experimentally inducing mild zinc deficiency in young healthy men reduced serum testosterone by nearly 75% over 20 weeks. Repletion reversed the decline [4]. In a separate supplementation trial, Netter et al. showed that 50 mg elemental zinc daily for 45-90 days improved testosterone in men on hemodialysis with documented zinc depletion [5]. Cinar et al. found that four weeks of zinc sulfate supplementation (30 mg/day) combined with exhaustive exercise produced higher post-exercise testosterone levels compared to exercise alone in sedentary men [6].

These results share a pattern. Zinc supplementation works when a deficit exists. Loading zinc beyond physiologic need has not produced additional testosterone in replete individuals and carries a risk of copper depletion at doses above 40 mg/day. Checking a serum zinc or red blood cell zinc level before long-term supplementation is prudent.

Ashwagandha: The Best-Studied Adaptogen for Testosterone

Ashwagandha (Withania somnifera) has accumulated more RCT evidence for testosterone elevation than any other herbal supplement. The mechanism likely involves cortisol reduction and downstream HPG axis disinhibition rather than direct gonadal stimulation, which makes it theoretically well-suited for secondary hypogonadism tied to chronic stress.

Lopresti et al. conducted a 16-week randomized, double-blind, placebo-controlled crossover trial in 57 overweight men aged 40-70. Ashwagandha root extract at 600 mg/day (standardized to 21 mg withanolide glycosides) increased testosterone by 14.7% compared to placebo (P=0.004) and raised DHEA-S by 18.1% [7]. Salivary cortisol dropped 15.2% in the ashwagandha arm. Wankhede et al. reported a similar direction of effect: 300 mg twice daily of ashwagandha root extract increased testosterone from baseline in resistance-training men (N=57), though the between-group difference versus placebo was modest [8].

A 2022 systematic review and meta-analysis of 12 RCTs (N=973) published in Health Science Reports found a standardized mean difference of 1.19 (95% CI 0.51-1.87) favoring ashwagandha for total testosterone versus placebo [9]. Effect sizes were larger in men who were overweight, stressed, or fatigued at baseline.

Dr. Adrian Lopresti, the lead researcher on several of these trials, has noted: "Ashwagandha appears most effective in men with elevated psychological stress or suboptimal baseline testosterone, rather than in healthy young men with already normal levels" [7]. That aligns with its proposed cortisol-mediated mechanism.

Dosing in positive trials has ranged from 300-600 mg/day of root extract standardized for withanolides. Side effects in trials were mild and comparable to placebo.

Fenugreek: Modest Free Testosterone Effects

Fenugreek seed extract (Trigonella foenum-graecum) contains furostanolic saponins that may inhibit aromatase and 5-alpha-reductase, theoretically shifting the testosterone-to-estrogen ratio.

Rao et al. randomized 120 healthy men aged 43-70 to 600 mg/day of a specialized fenugreek extract (Testofen) or placebo for 12 weeks. The supplement group showed a significant increase in free testosterone (from 15.0 to 19.8 pg/mL) while total testosterone remained unchanged [10]. Sexual function scores also improved. Wilborn et al. reported a similar free testosterone finding in resistance-trained college-aged men, though the clinical significance of free testosterone changes without total testosterone changes remains debated [11].

These trials are small and sponsored by ingredient manufacturers. The observed effect on free testosterone without a matching rise in total testosterone suggests fenugreek may influence sex hormone-binding globulin (SHBG) or aromatase activity rather than gonadotropin secretion. For men with secondary hypogonadism specifically, fenugreek has not been studied, and extrapolation from these healthy-male trials requires caution. If a man chooses to try it, 600 mg/day of a furostanolic saponin-standardized extract mirrors the positive trial protocols.

D-Aspartic Acid: Early Promise, Poor Replication

D-aspartic acid (DAA) stimulates GnRH and LH release in animal models and generated significant online enthusiasm after Topo et al. reported a 42% increase in testosterone in 23 men given 3.12 g/day of DAA for 12 days [12]. LH rose by 33%, consistent with a hypothalamic-pituitary mechanism.

That result did not replicate. Willoughby and Leutholtz gave 3 g/day of DAA to resistance-trained men for 28 days and found no change in total or free testosterone versus placebo [13]. Melville et al. confirmed the null finding in a similar population. The Topo trial used untrained, relatively sedentary men, and the testosterone increase may have reflected a transient spike that does not sustain over longer periods. DAA cannot be recommended as a reliable intervention for secondary hypogonadism based on current evidence.

Magnesium: Correlated With Testosterone, but Causation Is Thin

Epidemiologic data consistently link low magnesium intake to lower testosterone. Cinar et al. showed that magnesium supplementation (10 mg/kg/day) for four weeks raised both total and free testosterone in both athletes and sedentary men, with larger effects when combined with exercise [6]. A cross-sectional study in 399 older Italian men found that serum magnesium independently predicted testosterone levels after adjusting for age and BMI [14].

The RCT evidence is limited to that single four-week Cinar trial with a small sample. Still, given that over 50% of U.S. adults consume less than the estimated average requirement for magnesium, repletion is reasonable as a general health measure. Magnesium glycinate or citrate at 200-400 mg/day before bed also supports sleep quality, which itself influences testosterone.

Weight Loss: The Most Powerful Non-Pharmacologic Intervention

For men whose secondary hypogonadism is obesity-associated, losing weight is far more effective than any supplement.

Corona et al. conducted a systematic review and meta-analysis of 24 studies (N=2,029) and found that lifestyle-induced weight loss increased total testosterone by a mean of 2.9 nmol/L (84 ng/dL) in men who achieved at least 5% body weight reduction [15]. In the subset with obesity-associated secondary hypogonadism, normalization of testosterone was common. Camacho et al., analyzing data from the European Male Ageing Study (N=2,736), reported that a BMI decrease of more than 2 kg/m² over 4.4 years was associated with a testosterone increase equivalent to turning back the hormonal clock by a decade [16].

The mechanism is straightforward. Excess adipose tissue increases aromatase activity, converting testosterone to estradiol. The resulting hyperestrogenemia suppresses hypothalamic GnRH pulse frequency, reducing LH and FSH secretion. Reduce the fat mass, and the HPG axis regains sensitivity. The American Urological Association's 2018 guideline on testosterone deficiency explicitly recommends weight loss and exercise optimization as first-line therapy for obese men with low testosterone before considering pharmacotherapy.

Resistance training amplifies the effect. Kumagai et al. demonstrated that increased physical activity had a greater effect on testosterone recovery than caloric restriction alone in men with metabolic syndrome [17]. A program combining three to four resistance-training sessions per week with a moderate caloric deficit (500-750 kcal/day) represents the best-studied approach.

Sleep Optimization: A Modifiable and Underappreciated Driver

Testosterone secretion follows a diurnal rhythm tightly linked to sleep architecture. Leproult and Van Cauter restricted healthy young men (aged 24 ± 4 years) to five hours of sleep per night for one week. Daytime testosterone levels fell by 10-15%, an effect equivalent to 10-15 years of aging [18]. The decline was most pronounced in the afternoon hours when men with secondary hypogonadism already tend to test lowest.

Obstructive sleep apnea (OSA) adds another layer. OSA is both a cause and a consequence of low testosterone in obese men. CPAP adherence for at least four hours per night has been shown to partially restore testosterone in some, though not all, trials [19]. Treating OSA before attributing all symptoms to hypogonadism is a standard recommendation from both the Endocrine Society and AASM.

Practical sleep targets for HPG axis health: 7-9 hours per night, consistent sleep and wake times, and treatment of any underlying sleep-disordered breathing.

What About Enclomiphene and hCG?

Supplements and lifestyle modifications have a ceiling. When those measures prove insufficient, prescription agents that preserve the HPG axis offer a next step before exogenous testosterone.

Enclomiphene citrate (the trans-isomer of clomiphene) blocks hypothalamic estrogen receptors, disinhibiting GnRH pulsatility and raising LH, FSH, and testosterone while maintaining spermatogenesis. In a 2014 phase III trial (ZA-304, N=173), enclomiphene 12.5 mg/day raised total testosterone from a mean baseline of 228 ng/dL to 375 ng/dL at 16 weeks while preserving sperm concentrations [20]. This agent is particularly relevant for younger men with secondary hypogonadism who want to preserve fertility.

Human chorionic gonadotropin (hCG) at 1,500-3 to 000 IU two to three times weekly directly stimulates testicular Leydig cells via the LH receptor. It bypasses the hypothalamic-pituitary defect while maintaining intratesticular testosterone and spermatogenesis [1]. Both enclomiphene and hCG require physician oversight, lab monitoring, and a confirmed diagnosis.

A Decision Framework: Matching Interventions to Root Cause

Not all secondary hypogonadism responds to the same strategy. Matching the intervention to the underlying driver determines whether supplements, lifestyle changes, or prescription therapy should come first.

If obesity is the primary contributor (BMI >30 with no other identifiable cause), weight loss through caloric deficit and resistance training should be the foundation. Vitamin D and zinc testing followed by repletion if deficient adds a low-risk layer. Ashwagandha at 600 mg/day is reasonable for men with concurrent stress or fatigue symptoms based on RCT data.

If chronic stress or poor sleep is dominant, sleep optimization and ashwagandha have the most relevant evidence. Magnesium before bed serves dual purposes.

If lifestyle optimization over 3-6 months does not restore testosterone above 300 ng/dL with symptom resolution, the 2018 Endocrine Society guideline supports initiating pharmacologic therapy [1]. For men who desire fertility, enclomiphene or hCG should be discussed before exogenous testosterone, which suppresses spermatogenesis.

Repeat lab testing (morning total testosterone, LH, FSH, prolactin, and estradiol) at 12-week intervals allows objective tracking. A rise in LH alongside rising testosterone confirms that the HPG axis is responding to the intervention rather than reflecting measurement noise.